In US4032531 an interesting series o of incapacitating agents prepared at Edgewood Arsenal is disclosed. These are made more interesting by the fact
that they do not appear in the agents listed in Appendix I of the NAS report 'Possible Long-Term Health Effects.'
The claim in this patent is that increasing molecular weight makes these 'polymeric' agents more potent. These are actually dimeric 4-piperidinols
linked by dibasic acids via ester groups.
Here is the ChemDraw graphic of the 4 compounds described in Claim 7 of this patent.
[Edited on 21-7-2008 by Ritter]
[Edited on 21-7-2008 by Ritter]
Ritter - 21-7-2008 at 08:01
Here are the 4 compounds found in Claim 6:
Ritter - 21-7-2008 at 08:16
Here are the structures of Examples 1 & 2:
Sauron - 21-7-2008 at 08:47
I am sure those are not muscarine-receptor type delerium-producing agents. They are more akin to opioids or skeletal muscle relaxants. Which of course
could be incap agents if they are potent enough.
Chemrox ought to have a look, he is our resident forum bona fide medicinal chemist.Ritter - 21-7-2008 at 10:31
Quote:
Originally posted by Sauron
I am sure those are not muscarine-receptor type delerium-producing agents. They are more akin to opioids or skeletal muscle relaxants. Which of course
could be incap agents if they are potent enough.
You are correct. These agents were intended to incapacitate by reducing muscle tone.
It's interesting to observe the MED50 number for Example 1. It would take almost 200 grams of agent to affect a 75 kg soldier.
[Edited on 21-7-2008 by Ritter]Sauron - 21-7-2008 at 14:16
Well, I was going to suggest a look at these in relation to the dissociatives EA spent a lot of time studying as well (e.g., phencyclidine) but after
that last detail, what is the point?
